United Therapeutics (NASDAQ:UTHR) Price Target Raised to $705.00

United Therapeutics (NASDAQ:UTHR) had its target price lifted by UBS Group from $655.00 to $705.00 in a report released on Thursday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

UTHR has been the subject of several other research reports. Oppenheimer boosted their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. TD Cowen boosted their price objective on United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Wells Fargo & Company lifted their price target on shares of United Therapeutics from $423.00 to $466.00 and gave the company an “equal weight” rating in a research note on Thursday, February 26th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $539.00.

United Therapeutics Trading Down 1.4%

Shares of NASDAQ UTHR opened at $478.16 on Thursday. United Therapeutics has a 1-year low of $266.98 and a 1-year high of $537.19. The company has a 50-day moving average of $482.51 and a two-hundred day moving average of $453.25. The company has a market cap of $20.96 billion, a PE ratio of 17.14, a P/E/G ratio of 1.72 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. During the same period last year, the company earned $6.19 earnings per share. The company’s revenue was up 7.4% on a year-over-year basis. As a group, equities research analysts forecast that United Therapeutics will post 24.48 earnings per share for the current year.

Insider Activity at United Therapeutics

In related news, CFO James Edgemond sold 21,000 shares of the business’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $478.60, for a total transaction of $10,050,600.00. Following the transaction, the chief financial officer directly owned 8,142 shares in the company, valued at approximately $3,896,761.20. The trade was a 72.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction on Monday, December 15th. The shares were sold at an average price of $496.30, for a total transaction of $11,166,750.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 377,184 shares of company stock valued at $183,015,947 over the last three months. Insiders own 10.30% of the company’s stock.

Institutional Trading of United Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of UTHR. Clearstead Advisors LLC lifted its holdings in United Therapeutics by 8.9% during the 3rd quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 23 shares during the last quarter. Independent Advisor Alliance grew its position in shares of United Therapeutics by 3.3% in the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock valued at $406,000 after purchasing an additional 27 shares during the last quarter. Bessemer Group Inc. increased its stake in shares of United Therapeutics by 2.6% during the third quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock worth $472,000 after purchasing an additional 28 shares during the period. Florida Financial Advisors LLC lifted its holdings in United Therapeutics by 5.4% during the 4th quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company’s stock worth $268,000 after purchasing an additional 28 shares during the last quarter. Finally, NDVR Inc. grew its holdings in United Therapeutics by 5.1% in the 4th quarter. NDVR Inc. now owns 616 shares of the biotechnology company’s stock valued at $300,000 after buying an additional 30 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

Key United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: UBS raised its price target on UTHR from $655 to $705 and kept a Buy rating — a notable analyst endorsement implying material upside that could attract buyers. Read More.
• Neutral Sentiment: Multiple sell‑side firms have recently increased targets and reiterated Buy/outperform views (Oppenheimer, HC Wainwright, TD Cowen); consensus remains a “Moderate Buy” with a mid‑range price target, supporting a constructive medium‑term thesis. Read More.
• Negative Sentiment: A wave of insider selling this week is pressuring sentiment: CEO Martine Rothblatt sold 9,500 shares (~$4.65M), and several directors/executives (Ray Kurzweil, Paul Mahon, Tommy G. Thompson and others) also sold blocks at roughly $483–$490 per share. These large, concentrated disposals can prompt near‑term weakness even if insiders retain stakes. Read More. Read More.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.